400 results on '"Vandertop WP"'
Search Results
2. Tumoren van het centrale zenuwstelsel
- Author
-
Vandertop, WP, Dirven, Clemens, Wesseling, P, Van den Bent, M., Verhoeff, Joost J C, Krieken, JHJM, Beets-Tan, RGH, Gelderblom, AJ, Olofsen, MJJ, Rutten, HJT, Neurosurgery, Pathology, and CCA - Treatment and quality of life
- Published
- 2020
3. Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage
- Author
-
Sondag, L, Schreuder, FHBM, Boogaarts, HD, Rovers, MM, Vandertop, WP, Dammers, R., Klijn, CJM, Sondag, L, Schreuder, FHBM, Boogaarts, HD, Rovers, MM, Vandertop, WP, Dammers, R., and Klijn, CJM
- Published
- 2020
4. Ruggenmergletsels:Spinal Cord Injuries
- Author
-
Vandertop, WP, Brouwer, O.F., Kramer, William, Besselaar, AT, Bessems, JHJM, Edwards, MJR, Goslings, JC, Heeg, M, Kloen, P, Leenen, LPH, and Wijnen, RMH
- Published
- 2019
5. Hersentumoren op de kinderleeftijd
- Author
-
Vandertop, WP, Molanus, D, Vuurden, D. G. van, Mir, SE, Vermeulen, R. Jeroen, Damen-Korbijn, Carin M., Kaspers, Gert-Jan L, Neurosurgery, and CCA - Treatment and quality of life
- Published
- 2019
6. Ruggenmergletsels: Spinal Cord Injuries
- Author
-
Vandertop, WP, Brouwer, O.F., Kramer, William, Besselaar, AT, Bessems, JHJM, Edwards, MJR, Goslings, JC, Heeg, M, Kloen, P, Leenen, LPH, Wijnen, RMH, and Neurosurgery
- Published
- 2019
7. Zenuwletsels bij kinderen
- Author
-
Vandertop, WP, van Ouwerkerk, Pim W.J.R., Kramer, WLM, Besselaar, AT, Bessems, JHJM, Edwards, MJR, Goslings, JC, Heeg, M, Kloen, P, Leenen, LPH, Wijnen, RMH, Neurosurgery, Kramer, WLM, Besselaar, AT, Bessems, JHJM, Edwards, MJR, Goslings, JC, Heeg, M, Kloen, P, Leenen, LPH, and Wijnen, RMH
- Subjects
business.industry ,Medicine ,business - Published
- 2019
8. Prehaemorrhage antiplatelet use in aneurysmal subarachnoid haemorrhage and its impact on clinical outcome
- Author
-
Sebök, M, Keller, E, Regli, L, Coert, BA, Vandertop, WP, Sardeha, A, Verbaan, D, Germans, M, Sebök, M, Keller, E, Regli, L, Coert, BA, Vandertop, WP, Sardeha, A, Verbaan, D, and Germans, M
- Published
- 2019
9. Imaging in resective brain surgery. Navigating between function and survival
- Author
-
Hoefnagels, FWA, Vandertop, WP, Vandertop, William, Versélewel de Witt Hamer, Philip, and Neurosurgery
- Published
- 2018
10. Probability Maps of Glioblastoma Indicate Variation in Surgical Decisions Between 10 Surgical Teams
- Author
-
Müller, DMJ, Robe, P, Van der Brink, W., Ardon, H., Idema, B., Kloet, F., Barkhof, Frederik, Vandertop, WP, Bello, L., Widhalm, G., Mandonnet, E., Berger, M., Versélewel de Witt Hamer, PC, Neurosurgery, Amsterdam Neuroscience - Systems & Network Neuroscience, CCA - Cancer biology and immunology, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Neuroscience - Brain Imaging, Radiology and nuclear medicine, CCA - Treatment and quality of life, and CCA - Imaging and biomarkers
- Abstract
INTRODUCTION The aim of glioblastoma surgery is to maximize the extent of resection, while preserving functional integrity. Standards are lacking for surgical decision-making and consequently surgical strategies may differ between neurosurgical teams. In this study, we quantitated and compared surgical decision-making throughout the brain between neurosurgical teams for patients with a glioblastoma using probability maps. METHODS All adults with first-time glioblastoma surgery in 2012-2013 from 10 tertiary referral centers for neurooncological care were included in this study. For each patient, pre- and postoperative tumor were manually segmented on MRI and aligned to standard brain space. Resection probability maps and biopsy probability maps were constructed in 1 mm resolution for each team's cohort. Brain regions with differential biopsy and resection results between teams were identified. RESULTS The study cohort consisted of 931 patients of whom 293 received a biopsy and 638 a resection. Biopsy probability maps demonstrated differences between teams in biopsy rate per brain location, such as for the left precuneus and superior parietal lobule, indicating variation in biopsy decisions. Resection probability maps demonstrated differences between teams in residual tumor rate per brain location, such as for the left saggital striatum and neighboring posterior corpus callosum, indicating variation in resection decisions. CONCLUSION Biopsy and resection probability maps indicate treatment variation between teams for patients with a glioblastoma. This conveys useful objective arguments for quality of care discussions between surgical teams for these patients.
- Published
- 2018
11. NIMG-38. QUALITY OF SURGICAL DECISION MAKING FOR PATIENTS WITH A GLIOBLASTOMA IS SIMILAR BETWEEN NEURO-ONCOLOGICAL CARE TEAMS FROM THE UNITED STATES OF AMERICA AND THE NETHERLANDS
- Author
-
Müller, DMJ, Vandertop, WP, Robe, P., Han, S, Barkhof, F, Berger, Mitch, Versélewel de Witt Hamer, PC, Neurosurgery, Amsterdam Neuroscience - Systems & Network Neuroscience, CCA - Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Neuroscience - Brain Imaging, and Radiology and nuclear medicine
- Abstract
INTRODUCTION The extent of resection is important to improve survival in patients with a glioblastoma. The neurosurgeon’s aim is to maximize the extent of resection, while preserving functional integrity. Standards to aid in patient counselling and guide surgical decision making are nevertheless lacking, hence quality of surgical care might differ between neuro-oncological care teams. In this study we present a novel volumetric method to quantify post-resection residual tumors throughout the brain for patient populations. This allows direct comparison of surgical results between care teams. METHODS All adults with first-time glioblastoma surgery in 2012-2013 in each of two Dutch and one United States tertiary referral centres for neuro-oncological care were included in this study. From each of these patient populations preoperative tumors and postoperative residual disease were segmented on MRI and registered to standard space. Brain maps of tumor and residual tumor locations were constructed for each country. Differences between these brain maps were analysed to explore patient selection and treatment variation. RESULTS This study cohort consisted of 403 patients (the Netherlands: 268; the United States: 135). Of these, 111 tumors were biopsied and 292 resected. Tumor localization maps illustrate established preferential sites for glioblastoma distributions for each cohort, indicating similar patient referral patterns, selection or recruitment. Resection probability maps demonstrate no differential residual tumor localization throughout the brain, indicating similar surgical decision making. Brain maps were reviewed by the care teams and arguments for future decision making were discussed. CONCLUSIONS Brain maps of tumor localization convey important information that can be used to compare neuro-oncological care teams in terms of patient selection. In addition, surgical decision making can be made explicit through resection probability maps. This novel volumetric approach can provide objective arguments for discussions between care teams on the quality of neurosurgical care for patients with a glioblastoma.
- Published
- 2017
12. Tumoren van het Zenuwstelsel
- Author
-
Vandertop, WP, Dirven, C.M.F., Van den Bent, M., Stalpers, LJA, Wesseling, P, Velde van de, Cock, Graaf van der, Winette, Krieken van, Han, Marijnen, Corrie, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Treatment and quality of life, Radiation Oncology, Amsterdam Neuroscience - Systems & Network Neuroscience, Amsterdam Neuroscience - Brain Imaging, and Pathology
- Published
- 2017
13. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma
- Author
-
van Zanten, S (Sophie), El-Khouly, FE, Jansen, MHA, Bakker, DP, Aliaga, ES, Haasbeek, CJA, Wolf, NI, Zwaan, C.M., Vandertop, WP, van Vuurden, DG, Kaspers, GJL, van Zanten, S (Sophie), El-Khouly, FE, Jansen, MHA, Bakker, DP, Aliaga, ES, Haasbeek, CJA, Wolf, NI, Zwaan, C.M., Vandertop, WP, van Vuurden, DG, and Kaspers, GJL
- Published
- 2017
14. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of Zr-89-Bevacizumab PET Imaging in Brain Tumor Models
- Author
-
Jansen MH, Lagerweij T, Sewing AC, Vugts DJ, van Vuurden DG, Molthoff CF, Caretti V, Veringa SJ, Petersen N, Carcaboso AM, Noske DP, Vandertop WP, Wesseling P, van Dongen GA, Kaspers GJ, and Hulleman E
- Abstract
The role of the VEGF inhibitor bevacizumab in the treatment of diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study the biodistribution and uptake of zirconium-89 (Zr-89)labeled bevacizumab in DIPG mouse models. Human E98-FM, U251-FM glioma cells, and HSJD-DIPG-007-FLUC primary DIPG cells were injected into the subcutis, pons, or striatum of nude mice. Tumor growth was monitored by bioluminescence imaging (BLI) and visualized by MRI. Seventy-two to 96 hours after Zr-89-bevacizumab injections, mice were imaged by positron emission tomography (PET), and biodistribution was analyzed ex vivo. High VEGF expression in human DIPG was confirmed in a publically available mRNA database, but no significant (89)-Zrbevacizumab uptake could be detected in xenografts located in the pons and striatum at an early or late stage of the disease. E98-FM, and to a lesser extent the U251-FM and HSJD-DIPG-007 subcutaneous tumors, showed high accumulation of Zr-89-bevacizumab. VEGF expression could not be demonstrated in the intracranial tumors by in situ hybridization (ISH) but was clearly present in the perinecrotic regions of subcutaneous E98-FM tumors. The poor uptake of Zr-89-bevacizumab in xenografts located in the brain suggests that VEGF targeting with bevacizumab has limited efficacy for diffuse infiltrative parts of glial brain tumors in mice. Translating these results to the clinic would imply that treatment with bevacizumab in patients with DIPG is only justified after targeting of VEGF has been demonstrated by Zr-89-bevacizumab immuno-PET. We aim to confirm this observation in a clinical PET study with patients with DIPG. (C)2016 AACR.
- Published
- 2016
15. Subarachnoid hemorrhage: Early evaluation and optimization of management
- Author
-
Germans, M.R., Vandertop, WP, Vandertop, William, Rinkel, Gabriel J. E., Verbaan, Dagmar, Coert, Bert A, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Treatment and quality of life
- Subjects
cardiovascular diseases ,nervous system diseases - Abstract
A subarachnoid hemorrhage (SAH) is a life-threatening disease that was first described in the 18th century, but it took until the early 20th century until the term "spontaneous subarachnoid hemorrhage" was introduced by the English neurologist Sir Charles P. Symonds. Nowadays, the term spontaneous SAH describes the presence of blood in the subarachnoid space that is not the result of a trauma.In approximately 85% of cases a SAH is caused by a rupture of an aneurysm on one of the intracranial arteries and this is called an aneurysmal SAH (aSAH). In 15% of all SAH patients no aneurysm is visualized on initial vascular imaging investigations, which classifies these patients into the group of non-aneurysmal SAH.Not only the initial hemorrhage, but also rebleeds and complications related to the hemorrhage affect the course of the disease and outcome. Therefore, multiple factors need to be addressed to improve the course of the disease and patients’ outcome. Early diagnosis and treatment of SAH patients with the goal to reduce rebleeds might contribute to this improvement.As this thesis encompasses both aSAH and non-aneurysmal SAH patients, it is split into two parts for a separate evaluation of both patient groups. The first aim of this thesis is to gain better insight into the rebleed risk in the early phase after aSAH and to examine options that can reduce the risk for a rebleed.The second aim is to assess whether routine MR-imaging of the spinal axis is useful in non-aneurysmal SAH patients to identify a treatable cause of the hemorrhage.
- Published
- 2015
16. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria
- Author
-
Jansen, MH, Veldhuijzen van Zanten, Sophie E., Aliaga, ES, Heymans, MW, Warmuth-Metz, M, Hargrave, D, van der Hoeven, EJ, Gidding, CE, de Bont, ES, Eshghi, OS, Reddingius, Roel, Peeters, CM, Schouten-van Meeteren, AYN, Gooskens, RHJ, Granzen, B, Paardekooper, GM, Janssens, GO, Noske, DP, Barkhof, F, Kramm, CM, Vandertop, WP, Kaspers, GJ, van Vuurden, DG, Jansen, MH, Veldhuijzen van Zanten, Sophie E., Aliaga, ES, Heymans, MW, Warmuth-Metz, M, Hargrave, D, van der Hoeven, EJ, Gidding, CE, de Bont, ES, Eshghi, OS, Reddingius, Roel, Peeters, CM, Schouten-van Meeteren, AYN, Gooskens, RHJ, Granzen, B, Paardekooper, GM, Janssens, GO, Noske, DP, Barkhof, F, Kramm, CM, Vandertop, WP, Kaspers, GJ, and van Vuurden, DG
- Published
- 2015
17. Mutational profiling of kinases in glioblastoma
- Author
-
Bleeker, FE, Lamba, S, Zanon, C, Molenaar, RJ, Hulsebos, TJM, Troost, D, van Tilborg, AA, Vandertop, WP, Leenstra, Sieger, Van Noorden, CJF, Bardelli, A, Bleeker, FE, Lamba, S, Zanon, C, Molenaar, RJ, Hulsebos, TJM, Troost, D, van Tilborg, AA, Vandertop, WP, Leenstra, Sieger, Van Noorden, CJF, and Bardelli, A
- Abstract
Background: Glioblastoma is a highly malignant brain tumor for which no cure is available. To identify new therapeutic targets, we performed a mutation analysis of kinase genes in glioblastoma. Methods: Database mining and a literature search identified 76 kinases that have been found to be mutated at least twice in multiple cancer types before. Among those we selected 34 kinase genes for mutation analysis. We also included IDH1, IDH2, PTEN, TP53 and NRAS, genes that are known to be mutated at considerable frequencies in glioblastoma. In total, 174 exons of 39 genes in 113 glioblastoma samples from 109 patients and 16 high-grade glioma (HGG) cell lines were sequenced. Results: Our mutation analysis led to the identification of 148 non-synonymous somatic mutations, of which 25 have not been reported before in glioblastoma. Somatic mutations were found in TP53, PTEN, IDH1, PIK3CA, EGFR, BRAF, EPHA3, NRAS, TGFBR2, FLT3 and RPS6KC1. Mapping the mutated genes into known signaling pathways revealed that the large majority of them plays a central role in the PI3K-AKT pathway. Conclusions: The knowledge that at least 50% of glioblastoma tumors display mutational activation of the PI3K-AKT pathway should offer new opportunities for the rational development of therapeutic approaches for glioblastomas. However, due to the development of resistance mechanisms, kinase inhibition studies targeting the PI3K-AKT pathway for relapsing glioblastoma have mostly failed thus far. Other therapies should be investigated, targeting early events in gliomagenesis that involve both kinases and non-kinases.
- Published
- 2014
18. Mutational profiling of glioblastoma
- Author
-
Bleeker, FE, Vandertop, WP, Vandertop, William, van Noorden, Cornelis J. F., Leenstra, Sieger, Bardelli, A, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Treatment and quality of life
- Published
- 2009
19. Medulloblastoom: ontwikkelingen in de therapie en moleculaire biologie
- Author
-
Schouten- van Meeteren, AYN, Reddingius, Roel, Oldenburger, F, Vandertop, WP, and Pediatrics
- Published
- 2007
20. Cerebral microdialysis as a monitoring method for brain injury
- Author
-
Peerdeman, SM, Vandertop, WP, Vandertop, William, Girbes, Armand, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Treatment and quality of life, and AII - Cancer immunology
- Published
- 2004
21. Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus. An analysis of indications, techniques and results
- Author
-
Grotenhuis, J.A., Vandertop, WP, Gabreels, FJM, Vandertop, William, van der Spek, JAN, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Treatment and quality of life
- Published
- 2000
22. Magnetic resonance spectroscopy in hydrocephalus
- Author
-
Braun, K. P. J., Nicolay, Klaas, Vandertop, WP, Tulleken, Cornelis A.F., Nicolay, K, Vandertop, William, Tulleken, Cornelius A. F., Gooskens, R.H.J.M., and Amsterdam Neuroscience - Neurovascular Disorders
- Published
- 2000
23. Anatomical Differences Determine Distribution of Adenovirus after Convection-Enhanced Delivery to the Rat Brain
- Author
-
Idema, S, Caretti, V, Lamfers, Martine, van Beusechem, VW, Noske, DP, Vandertop, WP, Dirven, Clemens, Idema, S, Caretti, V, Lamfers, Martine, van Beusechem, VW, Noske, DP, Vandertop, WP, and Dirven, Clemens
- Abstract
Background: Convection-enhanced delivery (CED) of adenoviruses offers the potential of widespread virus distribution in the brain. In CED, the volume of distribution (Vd) should be related to the volume of infusion (Vi) and not to dose, but when using adenoviruses contrasting results have been reported. As the characteristics of the infused tissue can affect convective delivery, this study was performed to determine the effects of the gray and white matter on CED of adenoviruses and similar sized super paramagnetic iron oxide nanoparticles (SPIO). Methodology/Principal Findings: We convected AdGFP, an adenovirus vector expressing Green Fluorescent Protein, a virus sized SPIO or trypan blue in the gray and white matter of the striatum and external capsule of Wistar rats and towards orthotopic infiltrative brain tumors. The resulting Vds were compared to Vi and transgene expression to SPIO distribution. Results show that in the striatum Vd is not determined by the Vi but by the infused virus dose, suggesting diffusion, active transport or receptor saturation rather than convection. Distribution of virus and SPIO in the white matter is partly volume dependent, which is probably caused by preferential fluid pathways from the external capsule to the surrounding gray matter, as demonstrated by co-infusing trypan blue. Distant tumors were reached using the white matter tracts but tumor penetration was limited. Conclusions/Significance: CED of adenoviruses in the rat brain and towards infiltrative tumors is feasible when regional anatomical differences are taken into account while SPIO infusion could be considered to validate proper catheter positioning and predict adenoviral distribution.
- Published
- 2011
24. Diagnostiek
- Author
-
de Gans, J, Thompson, J, Roord, J, Mouton, Johan, Vandertop, WP, Centr. Begel.org.v.Intercoll.,, and Medical Microbiology & Infectious Diseases
- Published
- 1997
25. Clinical Decision Rule for C-Spine Clearance in the Netherlands, a National Survey
- Author
-
Saltzherr, TP, primary, Goossens, A, additional, Haan, RJ de, additional, Beenen, LFM, additional, and Vandertop, WP, additional
- Published
- 2012
- Full Text
- View/download PDF
26. Long-term outcome of neurosurgical untethering on neurosegmental motor and ambulation levels
- Author
-
Schoenmakers, MAGC, primary, Gooskens, RHJM, additional, Gulmans, VAM, additional, Hanlo, PW, additional, Vandertop, WP, additional, Uiterwaal, CSPM, additional, and Helders, PJM, additional
- Published
- 2003
- Full Text
- View/download PDF
27. Oncolytic adenoviruses for treatment of brain tumours
- Author
-
Dirven, CMF, primary, Beusechem, VW van, additional, Lamfers, MLM, additional, Grill, J, additional, Gerritsen, WR, additional, and Vandertop, WP, additional
- Published
- 2002
- Full Text
- View/download PDF
28. Familial Colloid Cysts of the Third Ventricle
- Author
-
Vandertop Wp, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, and Other departments
- Subjects
Brain Diseases ,Third ventricle ,Colloid cyst ,Cysts ,business.industry ,Anatomy ,medicine.disease ,medicine.anatomical_structure ,medicine ,Humans ,Surgery ,Neurology (clinical) ,Bibliographies as Topic ,business ,Third Ventricle - Published
- 2001
29. Rapidly progressive enlargement of the fourth ventricle in the preterm infant with post‐haemorrhagic ventricular dilatation
- Author
-
Rademaker, KJ, primary, Govaert, P, additional, Vandertop, WP, additional, Gooskens, R, additional, Meiners, LC, additional, and Vries, LS de, additional
- Published
- 1995
- Full Text
- View/download PDF
30. Impact of secondary transfer on patients with severe traumatic brain injury.
- Author
-
Joosse P, Saltzherr TP, van Lieshout WA, van Exter P, Ponsen KJ, Vandertop WP, Goslings JC, TraumaNet AMC and collaborating hospitals, Joosse, Pieter, Saltzherr, Teun-Peter, van Lieshout, Willem A M, van Exter, Pieternel, Ponsen, Kees-Jan, Vandertop, W Peter, and Goslings, J Carel
- Published
- 2012
- Full Text
- View/download PDF
31. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis.
- Author
-
van Beijnum J, van der Worp HB, Buis DR, Al-Shahi Salman R, Kappelle LJ, Rinkel GJ, van der Sprenkel JW, Vandertop WP, Algra A, Klijn CJ, van Beijnum, Janneke, van der Worp, H Bart, Buis, Dennis R, Al-Shahi Salman, Rustam, Kappelle, L Jaap, Rinkel, Gabriël J E, van der Sprenkel, Jan Willem Berkelbach, Vandertop, W Peter, Algra, Ale, and Klijn, Catharina J M
- Abstract
Context: Outcomes following treatment of brain arteriovenous malformations (AVMs) with microsurgery, embolization, stereotactic radiosurgery (SRS), or combinations vary greatly between studies.Objectives: To assess rates of case fatality, long-term risk of hemorrhage, complications, and successful obliteration of brain AVMs after interventional treatment and to assess determinants of these outcomes.Data Sources: We searched PubMed and EMBASE to March 1, 2011, and hand-searched 6 journals from January 2000 until March 2011.Study Selection and Data Extraction: We identified studies fulfilling predefined inclusion criteria. We used Poisson regression analyses to explore associations of patient and study characteristics with case fatality, complications, long-term risk of hemorrhage, and successful brain AVM obliteration.Data Synthesis: We identified 137 observational studies including 142 cohorts, totaling 13,698 patients and 46,314 patient-years of follow-up. Case fatality was 0.68 (95% CI, 0.61-0.76) per 100 person-years overall, 1.1 (95% CI, 0.87-1.3; n = 2549) after microsurgery, 0.50 (95% CI, 0.43-0.58; n = 9436) after SRS, and 0.96 (95% CI, 0.67-1.4; n = 1019) after embolization. Intracranial hemorrhage rates were 1.4 (95% CI, 1.3-1.5) per 100 person-years overall, 0.18 (95% CI, 0.10-0.30) after microsurgery, 1.7 (95% CI, 1.5-1.8) after SRS, and 1.7 (95% CI, 1.3-2.3) after embolization. More recent studies were associated with lower case-fatality rates (rate ratio [RR], 0.972; 95% CI, 0.955-0.989) but increased rates of hemorrhage (RR, 1.02; 95% CI, 1.00-1.03). Male sex (RR, 0.964; 95% CI, 0.945-0.984), small brain AVMs (RR, 0.988; 95% CI, 0.981-0.995), and those with strictly deep venous drainage (RR, 0.975; 95% CI, 0.960-0.990) were associated with lower case fatality. Lower hemorrhage rates were associated with male sex (RR, 0.976, 95% CI, 0.964-0.988), small brain AVMs (RR, 0.988, 95% CI, 0.980-0.996), and brain AVMs with deep venous drainage (0.982, 95% CI, 0.969-0.996). Complications leading to permanent neurological deficits or death occurred in a median 7.4% (range, 0%-40%) of patients after microsurgery, 5.1% (range, 0%-21%) after SRS, and 6.6% (range, 0%-28%) after embolization. Successful brain AVM obliteration was achieved in 96% (range, 0%-100%) of patients after microsurgery, 38% (range, 0%-75%) after SRS, and 13% (range, 0%-94%) after embolization.Conclusions: Although case fatality after treatment has decreased over time, treatment of brain AVM remains associated with considerable risks and incomplete efficacy. Randomized controlled trials comparing different treatment modalities appear justified. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
32. Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement.
- Author
-
Belhawi SM, Hoefnagels FW, Baaijen JC, Sanchez Aliaga E, Reijneveld JC, Heimans JJ, Barkhof F, Vandertop WP, De Witt Hamer PC, Belhawi, Sinan M K, Hoefnagels, Friso W A, Baaijen, Johannes C, Aliaga, Esther Sanchez, Reijneveld, Jaap C, Heimans, Jan J, Barkhof, Frederik, Vandertop, W Peter, and Hamer, Philip C De Witt
- Abstract
Background: Standards for residual tumour measurement after resection of gliomas with no or minimal enhancement have not yet been established. In this study residual volumes on early and late postoperative T2-/FLAIR-weighted MRI are compared.Methods: A retrospective cohort included 58 consecutive glioma patients with no or minimal preoperative gadolinium enhancement. Inclusion criteria were first-time resection between 2007 and 2009 with a T2-/FLAIR-based target volume and availability of preoperative, early (<48 h) and late (1-7 months) postoperative MRI. The volumes of non-enhancing T2/FLAIR tissue and diffusion restriction areas were measured.Results: Residual tumour volumes were 22% smaller on late postoperative compared with early postoperative T2-weighted MRI and 49% smaller for FLAIR-weighted imaging. Postoperative restricted diffusion volume correlated with the difference between early and late postoperative FLAIR volumes and with the difference between T2 and FLAIR volumes on early postoperative MRI.Conclusion: We observed a systematic and substantial overestimation of residual non-enhancing volume on MRI within 48 h of resection compared with months postoperatively, in particular for FLAIR imaging. Resection-induced ischaemia contributes to this overestimation, as may other operative effects. This indicates that early postoperative MRI is less reliable to determine the extent of non-enhancing residual glioma and restricted diffusion volumes are imperative. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
33. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis.
- Author
-
van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, and Rinkel GJ
- Published
- 2009
- Full Text
- View/download PDF
34. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life.
- Author
-
Klein M, Engelberts NHJ, van der Ploeg HM, Kasteleijn-Nolst Trenité DGA, Aaronson NK, Taphoorn MJB, Baaijen H, Vandertop WP, Muller M, Postma TJ, and Heimans JJ
- Published
- 2003
35. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma.
- Author
-
Klein M, Postma TJ, Taphoorn MJB, Aaronson NK, Vandertop WP, Muller M, van der Ploeg HM, Heimans JJ, Klein, M, Postma, T J, Taphoorn, M J B, Aaronson, N K, Vandertop, W P, Muller, M, van der Ploeg, H M, and Heimans, J J
- Published
- 2003
- Full Text
- View/download PDF
36. Case 21-2006: a man with left-sided facial pain.
- Author
-
Vandertop WP, Lagerwaard FJ, Guzzi G, Eskander E, Rabinov J, and Barker FG III
- Published
- 2006
37. The translatome of glioblastoma.
- Author
-
Cornelissen FMG, He Z, Ciputra E, de Haas RR, Beumer-Chuwonpad A, Noske D, Vandertop WP, Piersma SR, Jiménez CR, Murre C, and Westerman BA
- Abstract
Glioblastoma (GB), the most common and aggressive brain tumor, demonstrates intrinsic resistance to current therapies, resulting in poor clinical outcomes. Cancer progression can be partially attributed to the deregulation of protein translation mechanisms that drive cancer cell growth. In this study, we present the translatome landscape of GB as a valuable data resource. Eight patient-derived GB sphere cultures (GSCs) were analyzed using ribosome profiling and messenger RNA (mRNA) sequencing. We investigated inter-cell-line differences through differential expression analysis at both the translatome and transcriptome levels. Translational changes post-radiotherapy were assessed at 30 and 60 min. The translation of non-coding RNAs (ncRNAs) was validated using in-house and public mass spectrometry (MS) data, whereas RNA expression was confirmed by quantitative PCR (qPCR). Our findings demonstrate that ribosome sequencing provides more detailed information than MS or transcriptional analyses. Transcriptional similarities among GSCs correlate with translational similarities, aligning with previously defined subtypes such as proneural and mesenchymal. Additionally, we identified a broad spectrum of open reading frame types in both coding and non-coding mRNA regions, including long non-coding RNAs (lncRNAs) and pseudogenes undergoing active translation. Translation of ncRNAs into peptides was independently confirmed by in-house data and external MS data. We also observed that translational regulation of histones (downregulated) and splicing factors (upregulated) occurs in response to radiotherapy. These data offer new insights into genome-wide protein synthesis, identifying translationally regulated genes and alternative translation initiation sites in GB under normal and radiotherapeutic conditions, providing a rich resource for GB research. Further functional validation of differentially expressed genes after radiotherapy is needed. Understanding translational control in GB can reveal mechanistic insights and identify currently unknown biomarkers, ultimately enhancing the diagnosis and treatment of this aggressive brain cancer., (© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
38. Clinical course of patients with conservatively managed cerebral cavernous malformations.
- Author
-
Sandmann ACA, Kempeneers MA, van den Berg R, Verbaan D, Vandertop WP, and Coutinho JM
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Treatment Outcome, Cohort Studies, Retrospective Studies, Cerebral Hemorrhage therapy, Radiosurgery, Hemangioma, Cavernous, Central Nervous System therapy, Hemangioma, Cavernous, Central Nervous System complications, Conservative Treatment
- Abstract
Introduction: There is uncertainty whether patients with a cerebral cavernous malformation (CCM) should undergo conservative or surgical treatment, resulting in practice variation among hospitals. Our objective was to report clinical outcomes of patients with primarily conservatively managed CCMs., Patients and Methods: This single-center cohort study included consecutive adult CCM patients, diagnosed in 2000-2023, who underwent conservative management as primary treatment strategy. Data were extracted from medical records, and we systematically conducted telephone and questionnaire follow-up. Functional status was assessed on the modified Rankin Scale (mRS)., Results: Of 345 patients, we included 265 patients with a CCM (median age 46 years; 45% male). At baseline, 131 (49%) patients presented with symptomatic hemorrhage (SH), and 134 (51%) with other symptoms or asymptomatically. During 58 months (IQR 35-94) median follow-up, 51 (19%) patients experienced a SH, 33 (12%) a seizure, and 13 (5%) focal neurological deficits. Fourteen (5%) patients underwent intervention (surgery n = 11, radiosurgery n = 4). Presentation with SH was associated with higher annual bleeding rates (6.0% vs 1.5%, p < 0.001), and higher cumulative 5-/10-year bleeding risks (31%/41% vs 7%, p < 0.001). Brainstem CCM was associated with higher cumulative 5-/10-year bleeding risks (27%/38% vs 17%/21%, p = 0.038). Nineteen (7%) patients died; two (0.8%) directly attributable to CCM. Of 246 surviving patients, 205 (83%) completed the questionnaire. At follow-up, 172/224 (77%) patients were functionally independent (mRS score ⩽2)., Discussion and Conclusion: The majority of conservatively managed CCM patients remained free of a SH during follow-up. Few patients required intervention, and death attributable to the CCM was rare. These data may help patient counseling and treatment decisions., Competing Interests: Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JMC received financial support from the Dutch Heart Foundation, Medtronic, Bayer and Boehringer (all fees were paid to his employer), and is co-founder and shareholder of TrianecT. RvdB has a non-personal hospital consultancy at Johnson & Johnson (CERENOVUS). All other authors declare that there is no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
39. Calculation of the minimum clinically important difference (MCID) using different methodologies: case study and practical guide.
- Author
-
Klukowska AM, Vandertop WP, Schröder ML, and Staartjes VE
- Subjects
- Humans, Outcome Assessment, Health Care methods, Surveys and Questionnaires standards, Minimal Clinically Important Difference, Spinal Stenosis surgery
- Abstract
Introduction: Establishing thresholds of change that are actually meaningful for the patient in an outcome measurement instrument is paramount. This concept is called the minimum clinically important difference (MCID). We summarize available MCID calculation methods relevant to spine surgery, and outline key considerations, followed by a step-by-step working example of how MCID can be calculated, using publicly available data, to enable the readers to follow the calculations themselves., Methods: Thirteen MCID calculations methods were summarized, including anchor-based methods, distribution-based methods, Reliable Change Index, 30% Reduction from Baseline, Social Comparison Approach and the Delphi method. All methods, except the latter two, were used to calculate MCID for improvement of Zurich Claudication Questionnaire (ZCQ) Symptom Severity of patients with lumbar spinal stenosis. Numeric Rating Scale for Leg Pain and Japanese Orthopaedic Association Back Pain Evaluation Questionnaire Walking Ability domain were used as anchors., Results: The MCID for improvement of ZCQ Symptom Severity ranged from 0.8 to 5.1. On average, distribution-based methods yielded lower MCID values, than anchor-based methods. The percentage of patients who achieved the calculated MCID threshold ranged from 9.5% to 61.9%., Conclusions: MCID calculations are encouraged in spinal research to evaluate treatment success. Anchor-based methods, relying on scales assessing patient preferences, continue to be the "gold-standard" with receiver operating characteristic curve approach being optimal. In their absence, the minimum detectable change approach is acceptable. The provided explanation and step-by-step example of MCID calculations with statistical code and publicly available data can act as guidance in planning future MCID calculation studies., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Impact of time to start of tranexamic acid treatment on rebleed risk and outcome in aneurysmal subarachnoid hemorrhage.
- Author
-
Germans MR, Tjerkstra MA, Post R, Brenner A, Vergouwen MD, Rinkel GJ, Roos YB, van den Berg R, Coert BA, Vandertop WP, and Verbaan D
- Subjects
- Humans, Female, Male, Middle Aged, Treatment Outcome, Adult, Aged, Time Factors, Recurrence, Time-to-Treatment, Tranexamic Acid therapeutic use, Tranexamic Acid administration & dosage, Subarachnoid Hemorrhage drug therapy, Antifibrinolytic Agents therapeutic use, Antifibrinolytic Agents administration & dosage
- Abstract
Introduction: The ULTRA-trial investigated effectiveness of ultra-early administration of tranexamic acid (TXA) in subarachnoid hemorrhage (SAH) and showed that TXA reduces the risk of rebleeding without concurrent improvement in clinical outcome. Previous trials in bleeding conditions, distinct from SAH, have shown that time to start of antifibrinolytic treatment influences outcome. This post-hoc analysis of the ULTRA-trial investigates whether the interval between hemorrhage and start of TXA impacts the effect of TXA on rebleeding and functional outcome following aneurysmal SAH., Patients and Methods: A post-hoc comparative analysis was conducted between aneurysmal SAH patients of the ULTRA-trial, receiving TXA and usual care to those receiving usual care only. We assessed confounders, hazard ratio (HR) of rebleeding and odds ratio (OR) of good outcome (modified Rankin Scale 0-3) at 6 months, and investigated the impact of time between hemorrhage and start of TXA on the treatment effect, stratified into time categories (0-3, 3-6 and >6 h)., Results: Sixty-four of 394 patients (16.2%) in the TXA group experienced a rebleeding, compared to 83 of 413 patients (19.9%) with usual care only (HR 0.86, 95% confidence interval (CI): 0.62-1.19). Time to start of TXA modifies the effect of TXA on rebleeding rate ( p < 0.001), with a clinically non-relevant reduction observed only when TXA was initiated after 6 h (absolute rate reduction 1.4%). Tranexamic acid treatment showed no effect on good outcome (OR 0.96, 95% CI: 0.72-1.27) with no evidence of effect modification on the time to start of TXA ( p = 0.53)., Discussion and Conclusions: This study suggests that the effect of TXA on rebleeding is modified by time to treatment, providing a protective, albeit clinically non-relevant, effect only when started after 6 h. No difference in functional outcome was seen. Routine TXA treatment in the aneurysmal SAH population, even within a specified time frame, is not recommended to improve functional outcome., Competing Interests: Declaration of Conflicting InterestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MDIV reports funding from the Dutch Heart Foundation (clinical established investigator grant number 2018T0769). RvdB reports grants from Cerenovus neurovascular, outside the submitted work; YBWEMR is a minor shareholder of Nico-Lab. All other authors declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
41. Plasma Neurofilament Light Chain as a Biomarker for Poor Outcome After Aneurysmal Subarachnoid Hemorrhage.
- Author
-
Labib H, Tjerkstra MA, Teunissen CE, Horn J, Vermunt L, Coert BA, Post R, Vandertop WP, and Verbaan D
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Adult, Cohort Studies, Prognosis, Treatment Outcome, Subarachnoid Hemorrhage blood, Subarachnoid Hemorrhage surgery, Neurofilament Proteins blood, Biomarkers blood
- Abstract
Background: Neurofilament light chain (NfL), a biomarker reflecting neuro-axonal damage, may be useful in improving clinical outcome prediction after aneurysmal subarachnoid hemorrhage (aSAH). We explore the robust and additional value of NfL to neurologic and radiologic grading scales in predicting poor outcome after aSAH., Methods: In this prospective cohort study conducted in a single tertiary center, blood samples were collected of aSAH patients within 24 hours after ictus and before endovascular/surgical intervention. The primary endpoint was poor outcome at 6 months' follow-up. Receiver operating curves (ROC), area under the curve (AUC, 95% CI) and model-fit (Nagelkerke R
2 ) were calculated for NfL, neurologic grading scale (WFNS), modified Fisher, age ,and sex. A combined ROC and AUC were calculated for variables with an AUC ≥ 0.70., Results: A total of 66 (42%) had poor outcome. The AUC of NfL for poor outcome was 0.70 (0.62-0.78). Combining NfL and WFNS resulted in a slightly higher model fit and not-significantly higher AUC for predicting poor outcome (R2 0.51; AUC 0.86, 0.80-0.92) compared with WFNS alone. When patients were stratified according to hemorrhage severity, median NfL [IQR] levels were significantly higher in poor grade (14 [7-32] pg/mL) than good grade patients (7 [5-14] pg/mL). Within poor grade patients, median NfL [IQR] levels were significantly higher in non-survivors (19 [11-36] pg/mL) than survivors (7 [6-13] pg/mL)., Conclusion: In the entire aSAH cohort, plasma NfL has an acceptable predictive performance but does not improve clinical outcome prediction. However, NfL may have potential value in subgroups based on hemorrhage severity., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
42. Medical Malpractice in Neurosurgery: An Analysis of Claims in the Netherlands.
- Author
-
Dronkers WJ, Buis DR, Amelink QJMA, Bouma GJ, Peul WC, Vandertop WP, Broekman MLD, Hendriks AC, Dirven CMF, and Spoor JKH
- Abstract
Background and Objectives: Studying malpractice claims is important to improve quality of health care and patient safety and to educate the individual healthcare providers. The objective of this study was to describe characteristics of neurosurgical claims in the Netherlands., Methods: A nationwide retrospective observational study of neurosurgery-related claims closed by Centramed and MediRisk, 2 major insurance companies in the Netherlands, was performed. Relevant data, including type of neurosurgical pathology, theme and category of the claim, type and severity of injury, outcome, and financial burden, were extracted from anonymized claim files. The estimated annual risk was used to determine the risk for claims by adjusting for the number of annually practicing neurosurgeons in the Netherlands., Results: A total of 388 claims against neurosurgeons were closed between 2007 and 2021. Liability was denied in a slight majority of claims (n = 230; 59%). The total burden during this period was €6 165 000 (amount paid out to patients: €5 497 000). The estimated annual risk per Dutch neurosurgeon for a claim was 15.5%, meaning 1 claim per 6.5 years. The case-level analysis of 238 available anonymized claims revealed that most claims were related to spinal pathology (81.5%), followed by cranial pathology (10.9%) and peripheral nerve (7.6%). The motivations for filing claims were mostly related to alleged surgical (56.3%) or diagnostic errors (22.3%). Most of these claims were denied (151/238; 63.4%), and fewer were settled (42/238; 17.6%), sustained (31/238; 13.0%), or closed without final decision (14/238; 5.9%)., Conclusion: Neurosurgery-related malpractice claims primarily involved spinal pathology and were mostly related to alleged treatment errors. Most claims did not result in compensation because there seemed to be no liability or culpable injury. However, the annual risk for a claim for Dutch neurosurgeons is considerable., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.)
- Published
- 2024
- Full Text
- View/download PDF
43. Ultra-Early and Short-Term Tranexamic Acid Treatment in Patients With Good- and Poor-Grade Aneurysmal Subarachnoid Hemorrhage.
- Author
-
Tjerkstra MA, Post R, Germans MR, Vergouwen MDI, Jellema K, Koot RW, Kruyt ND, Wolfs JFC, De Beer FC, Kieft HH, Nanda D, Van Der Pol B, Roks G, De Beer F, Reichman LJA, Brouwers PJAM, Kwa VIH, Van Der Ree TC, Bienfait HP, Boogaarts HD, Klijn CJ, Visser V, van den Berg R, Coert BA, Horn J, Majoie CBLM, Rinkel GJE, Roos YBWEM, Vandertop WP, and Verbaan D
- Subjects
- Humans, Female, Male, Middle Aged, Treatment Outcome, Aged, Prospective Studies, Adult, Tranexamic Acid therapeutic use, Tranexamic Acid administration & dosage, Subarachnoid Hemorrhage drug therapy, Antifibrinolytic Agents therapeutic use, Antifibrinolytic Agents administration & dosage
- Abstract
Background and Objectives: The results of the ULTRA trial showed that ultra-early and short-term treatment with tranexamic acid (TXA) does not improve clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH). Possibly, the lack of a beneficial effect in all patients with aSAH is masked by antagonistic effects of TXA in certain subgroups. In this post hoc subgroup analysis, we investigated the effect of TXA on clinical outcome in patients with good-grade and poor-grade aSAH., Methods: The ULTRA trial was a multicenter, prospective, randomized, controlled, open-label trial with blinded outcome assessment. Participants received ultra-early and short-term TXA in addition to usual care or usual care only. This post hoc subgroup analysis included only ULTRA participants with confirmed aSAH and available World Federation of Neurosurgical Societies (WFNS) grade on admission. Patients were categorized into those with good-grade (WFNS 1-3) and poor-grade (WFNS 4-5) aSAH. The primary outcome was clinical outcome assessed by the modified Rankin scale (mRS). Odds ratios (ORs) and adjusted ORs (aORs) with 95% CIs were calculated using ordinal regression analyses. Analyses were performed using the as-treated principle. In all patients with aSAH, no significant effect modification of TXA on clinical outcome was observed for admission WFNS grade ( p = 0.10)., Results: Of the 812 ULTRA participants, 473 patients had (58%; N = 232 TXA, N = 241 usual care) good-grade and 339 (42%; N = 162 TXA, N = 176 usual care) patients had poor-grade aSAH. In patients with good-grade aSAH, the TXA group had worse clinical outcomes (OR: 0.67, 95% CI 0.48-0.94, aOR 0.68, 95% CI 0.48-0.94) compared with the usual care group. In patients with poor-grade aSAH, clinical outcomes were comparable between treatment groups (OR: 1.04, 95% CI 0.70-1.55, aOR 1.05, 95% CI 0.70-1.56)., Discussion: This post hoc subgroup analysis provides another important argument against the use of TXA treatment in patients with aSAH, by showing worse clinical outcomes in patients with good-grade aSAH treated with TXA and no clinical benefit of TXA in patients with poor-grade aSAH, compared with patients treated with usual care., Trial Registration Information: ClinicalTrials.gov (NCT02684812; submission date February 18, 2016, first patient enrollment on July 24, 2013)., Classification of Evidence: This study provides Class II evidence that tranexamic acid, given for <24 hours within the first 24 hours, does not improve the 6-month outcome in good-grade or poor initial-grade aneurysmal SAH.
- Published
- 2024
- Full Text
- View/download PDF
44. Resilience After High-Grade Subarachnoid Hemorrhage: A Prospective Cohort Study on Quality of Life.
- Author
-
Denneman N, Post R, Coert BA, van den Berg R, Verbaan D, and Vandertop WP
- Abstract
Background and Objectives: Treatment of patients who present with poor clinical condition is often postponed until neurological improvement is observed. Despite previous studies, it is still unclear how survivors perceive their quality of life (QoL). This study aimed to evaluate self-perceived QoL in patients with aneurysmal subarachnoid hemorrhage who present with poor clinical condition, as defined by World Federation of Neurosurgical Societies (WFNS) grades 4 to 5, compared with those who present in more favorable clinical condition (WFNS 1-3)., Methods: Between 2011 and 2021, 1160 patients with aneurysmal subarachnoid hemorrhage were admitted to the Amsterdam UMC. Among the 845 patients who survived, 537 participated in the QoL questionnaires. Patient characteristics, complications, EQ-5D questionnaires, modified Rankin Scale, and Hospital Anxiety and Depression Scale were analyzed using the nonparametric Mann-Whitney U test for continuous variables or the Pearson χ2 test for categorical variables., Results: Of the 537 responders, 452 (84%) presented with low grade (WFNS 1-3) and 85 (16%) presented with high grade (WFNS 4-5). The high-grade group reported a self-perceived QoL score of 70 (of 100), while the low-grade group reported a score of 75 (P = .12). The mean EQ-5D index value was 0.74 for the high-grade group and 0.81 for the low-grade group (P < .01). In the high-grade group, 61 patients (72%) had a favorable outcome (modified Rankin Scale 0-3) compared with 419 (94%) in the low-grade group (P < .001)., Conclusion: High-grade WFNS patients rated their QoL as satisfactory, with only a marginal 5-point difference on a 100-point scale compared with low-grade WFNS patients. In addition, almost three-quarters of high-grade WFNS survivors achieved a favorable outcome. Given that a subset of patients, despite presenting with a poor clinical condition, still achieve a favorable outcome, these findings reinforce our perspective advocating for early and comprehensive treatment., (Copyright © Congress of Neurological Surgeons 2024. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. The long-term outcome of revision microdiscectomy for recurrent sciatica.
- Author
-
Lequin MB, Verbaan D, Schuurman PR, Tasche S, Peul WC, Vandertop WP, and Bouma GJ
- Subjects
- Humans, Middle Aged, Male, Female, Treatment Outcome, Aged, Recurrence, Adult, Microsurgery methods, Lumbar Vertebrae surgery, Pain Measurement, Radiculopathy surgery, Sciatica surgery, Sciatica etiology, Diskectomy methods, Reoperation statistics & numerical data
- Abstract
Purpose: To study the long-term outcome of revision microdiscectomy after classic microdiscectomy for lumbosacral radicular syndrome (LSRS)., Methods: Eighty-eight of 216 patients (41%) who underwent a revision microdiscectomy between 2007 and 2010 for MRI disc-related LSRS participated in this study. Questionnaires included visual analogue scores (VAS) for leg pain, RDQ, OLBD, RAND-36, and seven-point Likert scores for recovery, leg pain, and back pain. Any further lumbar re-revision operation(s) were recorded., Results: Mean (SD) age was 59.8 (12.8), and median [IQR] time of follow-up was 10.0 years [9.0-11.0]. A favourable general perceived recovery was reported by 35 patients (40%). A favourable outcome with respect to perceived leg pain was present in 39 patients (45%), and 35 patients (41%) reported a favourable outcome concerning back pain. The median VAS for leg and back pain was worse in the unfavourable group (48.0/100 mm (IQR 16.0-71.0) vs. 3.0/100 mm (IQR 2.0-5.0) and 56.0/100 mm (IQR 27.0-74.0) vs. 4.0/100 mm (IQR 2.0-17.0), respectively; both p < 0.001). Re-revision operation occurred in 31 (35%) patients (24% same level same side); there was no significant difference in the rate of favourable outcome between patients with or without a re-revision operation., Conclusion: The long-term results after revision microdiscectomy for LSRS show an unfavourable outcome in the majority of patients and a high risk of re-revision microdiscectomy, with similar results. Based on also the disappointing results of alternative treatments, revision microdiscectomy for recurrent LSRS seems to still be a valid treatment. The results of our study may be useful to counsel patients in making appropriate treatment choices., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
46. Torticollis with Atlantoaxial Rotatory Subluxation in Children: A Clinical Review.
- Author
-
Kempeneers MA, Buis DR, Feller RE, Roosendaal SD, Slot KM, Wolf NI, and Vandertop WP
- Abstract
A small proportion of children with a sudden onset torticollis ("wry neck") presents with an atlantoaxial rotatory subluxation, usually after mild trauma or recent head or neck infection. Torticollis is a clinical diagnosis and imaging is usually not indicated, though often performed in clinical practice. Atlantoaxial rotatory subluxation on imaging is often a physiological phenomenon in torticollis, and concomitant neurological symptoms are therefore rare. Treatment is primarily conservative, with analgesics, a rigid neck collar, and if needed benzodiazepines to counteract muscle spasms and anxiety. In case of treatment failure or chronic subluxation, cervical repositioning and fixation under general anesthesia may be considered. Surgical treatment is only indicated in a small percentage of patients with chronic refractory subluxation, concomitant cervical fractures, or congenital anomalies. Early diagnosis and treatment are important, since this is associated with a more successful conservative outcome than a prolonged approach., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Under pressure - A historical vignette on surgical timing in traumatic spinal cord injury.
- Author
-
Ter Wengel PV, Reith F, Adegeest CY, Fehlings MG, Kwon BK, Vandertop WP, and Öner CF
- Abstract
Introduction: It was not even a century ago when a spinal cord injury (SCI) would inevitably result in a fatal outcome, particularly for those with complete SCI. Throughout history, there have been extensive endeavours to change the prospects for SCI patients by performing surgery, even though many believed that there was no way to alter the catastrophic course of SCI. To this day, the debate regarding the efficacy of surgery in improving the neurological outcome for SCI patients persists, along with discussions about the timing of surgical intervention., Research Question: How have the historical surgical results shaped our perspective on the surgical treatment of SCI?, Material and Methods: Narrative literature review., Results: Throughout history there have been multiple surgical attempts to alter the course of SCI, with conflicting results. While studies suggest a potential link between timing of surgery and neurological recovery, the exact impact of immediate surgery on individual cases remains ambiguous. It is becoming more evident that, alongside surgical intervention, factors specific to both the patient and their surgical treatment will significantly influence neurological recovery., Conclusion: Although a growing number of studies indicates a potential correlation of surgical timing and neurological outcome, the precise influence of urgent surgery on an individual basis remains uncertain. It is increasingly apparent that, despite surgery, patient- and treatment-specific factors will also play a role in determining the neurological outcome. Notably, these very factors have influenced the results in previous studies and our views concerning surgical timing., Competing Interests: None., (© 2024 The Authors. Published by Elsevier B.V. on behalf of EUROSPINE, the Spine Society of Europe, EANS, the European Association of Neurosurgical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
48. Sodium and Its Impact on Outcome After Aneurysmal Subarachnoid Hemorrhage in Patients With and Without Delayed Cerebral Ischemia.
- Author
-
Labib H, Tjerkstra MA, Coert BA, Post R, Vandertop WP, Verbaan D, and Müller MCA
- Subjects
- Adult, Humans, Prospective Studies, Sodium, Subarachnoid Hemorrhage complications, Hypernatremia complications, Hyponatremia etiology, Brain Ischemia complications
- Abstract
Objectives: To perform a detailed examination of sodium levels, hyponatremia and sodium fluctuations, and their association with delayed cerebral ischemia (DCI) and poor outcome after aneurysmal subarachnoid hemorrhage (aSAH)., Design: An observational cohort study from a prospective SAH Registry., Setting: Tertiary referral center focused on SAH treatment in the Amsterdam metropolitan area., Patients: A total of 964 adult patients with confirmed aSAH were included between 2011 and 2021., Interventions: None., Measurements and Main Results: A total of 277 (29%) developed DCI. Hyponatremia occurred significantly more often in DCI patients compared with no-DCI patients (77% vs. 48%). Sodium levels, hyponatremia, hypernatremia, and sodium fluctuations did not predict DCI. However, higher sodium levels were significantly associated with poor outcome in DCI patients (DCI onset -7, DCI +0, +1, +2, +4, +5, +8, +9 d), and in no-DCI patients (postbleed day 6-10 and 12-14). Also, hypernatremia and greater sodium fluctuations were significantly associated with poor outcome in both DCI and no-DCI patients., Conclusions: Sodium levels, hyponatremia, and sodium fluctuations were not associated with the occurrence of DCI. However, higher sodium levels, hypernatremia, and greater sodium fluctuations were associated with poor outcome after aSAH irrespective of the presence of DCI. Therefore, sodium levels, even with mild changes in levels, warrant close attention., Competing Interests: Dr. Labib disclosed work for hire. The remaining authors have disclosed that they do not have any potential conflicts of interest., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
49. Identifying clusters of objective functional impairment in patients with degenerative lumbar spinal disease using unsupervised learning.
- Author
-
Staartjes VE, Klukowska AM, Stumpo V, Vandertop WP, and Schröder ML
- Subjects
- Humans, Male, Female, Child, Lumbar Vertebrae surgery, Prospective Studies, Unsupervised Machine Learning, Pain Measurement methods, Intervertebral Disc Degeneration complications, Intervertebral Disc Degeneration surgery
- Abstract
Objectives: The five-repetition sit-to-stand (5R-STS) test was designed to capture objective functional impairment (OFI), and thus provides an adjunctive dimension in patient assessment. It is conceivable that there are different subsets of patients with OFI and degenerative lumbar disease. We aim to identify clusters of objectively functionally impaired individuals based on 5R-STS and unsupervised machine learning (ML)., Methods: Data from two prospective cohort studies on patients with surgery for degenerative lumbar disease and 5R-STS times of ≥ 10.5 s-indicating presence of OFI. K-means clustering-an unsupervised ML algorithm-was applied to identify clusters of OFI. Cluster hallmarks were then identified using descriptive and inferential statistical analyses., Results: We included 173 patients (mean age [standard deviation]: 46.7 [12.7] years, 45% male) and identified three types of OFI. OFI Type 1 (57 pts., 32.9%), Type 2 (81 pts., 46.8%), and Type 3 (35 pts., 20.2%) exhibited mean 5R-STS test times of 14.0 (3.2), 14.5 (3.3), and 27.1 (4.4) seconds, respectively. The grades of OFI according to the validated baseline severity stratification of the 5R-STS increased significantly with each OFI type, as did extreme anxiety and depression symptoms, issues with mobility and daily activities. Types 1 and 2 are characterized by mild to moderate OFI-with female gender, lower body mass index, and less smokers as Type I hallmarks., Conclusions: Unsupervised learning techniques identified three distinct clusters of patients with OFI that may represent a more holistic clinical classification of patients with OFI than test-time stratifications alone, by accounting for individual patient characteristics., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
50. [Subarachnoid hemorrhage in a young girl].
- Author
-
Lodewijkx R, Draijer L, de Ridder R, Eikelenboom MJ, Coert BA, Meeuwes M, and Vandertop WP
- Subjects
- Child, Female, Humans, Headache, Nausea, Vomiting, Subarachnoid Hemorrhage diagnosis, Subarachnoid Hemorrhage etiology, Subarachnoid Hemorrhage surgery, Aneurysm
- Abstract
Background: Subarachnoid hemorrhage in children is rare. The most common cause is trauma, followed by an arteriovenous malformation, aneurysm or tumor., Case Description: We describe the case of an 11-year-old girl who developed sudden headache with nausea and vomiting during athletics training. Her neurological exam was normal. With imaging and a lumbar puncture a subarachnoid hemorrhage was diagnosed, based on a ruptured saccular aneurysm of the right middle cerebral artery. Endovascular treatment was unsuccessful, after which the aneurysm was treated surgically. Postoperative recovery was uneventful. Additional tests for underlying conditions were negative., Conclusion: Also in a child with acute headache, nausea, and vomiting, the diagnosis of a subarachnoid hemorrhage should be considered, even if neurological examination is normal. Expeditious diagnosis and treatment are important in order to prevent rebleeding.
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.